Combination drug therapy for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, trilaciclib and immunotherapy, for people with head and neck squamous cell carcinoma that has spread or come back and can't be treated with surgery or radiation. The goal is to see if this combination helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with squamous cell carcinoma of the head and neck that is recurrent or metastatic (spread) and not treatable with local therapy like surgery or radiation.
- If your cancer is only recurrent (not spread), you must have had radiation therapy that finished more than 6 months ago.
- You have at least one tumor that can be measured by imaging (like CT or MRI).
- Your blood counts and organ function are within acceptable ranges (your doctor will check with blood tests).
- You are able to perform daily activities with little or no help (ECOG score 0 or 1) and expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a new combination of two investigational drugs (adebrelimab and dalpiciclib) given before surgery for locally advanced head and neck cancer that is not linked to HPV. The goal is to see if these drugs can shrink the tumor and possibly improve outcomes.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
This trial tests a combination of three drugs—methotrexate, erlotinib, and celecoxib—for people whose head and neck cancer has come back or spread. It is designed for patients in the rural Midwest who have already had or chosen not to have standard first treatment.
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
Hear when a new Head & Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.